TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03375190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing
Description: Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing + adhesive
Description: Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips (parallel)
Description: Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips (perpend)
Description: Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips + benzoin
Description: Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips + spray
Description: Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
Study: NCT01445028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin 20mg daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin 20mg daily for 12 weeks
Study: NCT04655664

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: not currently consumed vitamin D supplements regularly
Description: The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: consumed vitamin D supplements regularly
Description: The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
Study: NCT05797324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luminette
Description: Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham protocol (white light \<100 lux equivalent).
Study: NCT02705638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
Study: NCT01550497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised spinal stabilization exercises
Description: Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised spinal stabilization exercises
Description: Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
Study: NCT03224273

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proximal box inlay retained bridge
Description: inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal box inlay retained bridge
Description: inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
Study: NCT02575521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol-Dexmedetomidine group
Description: Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane group
Description: Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
Study: NCT01028846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazoxide
Description: 1-2 mg/kg total dose given intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous normal saline
Study: NCT02001233

Intervention type: BIOLOGICAL
Intervention: EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
Study: NCT05101603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Abrasive
Description: Applied with Nd:YAG Laser on periodontal pockets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Applied with Air Abrasive on periodontal pockets

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
Study: NCT01169077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1300
Description: Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1300
Description: Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1300
Description: Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
Study: NCT02559466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS - ) - MagPro®
Description: Class IIa

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS - ) - MagPro®
Description: Class IIa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positon Emission Tomography (PET) - Discovery 710®
Description: Class IB

Intervention type: DEVICE
Group type: OTHER
Intervention: Positon Emission Tomography (PET) - Discovery 710®
Description: Class IB
Study: NCT04993378

Intervention type: DEVICE
Intervention: EV-array
Description: Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT01200901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: quetiapine XR 100 - 300 mg (flexible dosing)
Study: NCT01654510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Group
Description: This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vocational Services as Usual
Study: NCT01339546

Intervention type: OTHER
Intervention: no intervention
Study: NCT02995616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regular therapy settings
Description: Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 100% guidance force
Description: Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 60% guidance force
Description: Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
Study: NCT02549768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
Study: NCT02326558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic microwave ablation-assisted enucleation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic partial nephrectomy
Study: NCT01134965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin plus Digoxin
Description: Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin 0.5 mg as single dose
Study: NCT01240460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Supplied as 10-mg and/or 50-mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Supplied as 10-mg and/or 50-mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Supplied as 100-mg, 150-mg and/or 200-mg tablets
Study: NCT02811692

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study: NCT03344003

Intervention type: DRUG
Intervention: Wilate or Nuwiq
Description: Wilate or Nuwiq administered via intravenous injection

Intervention type: DRUG
Intervention: Wilate or Nuwiq
Description: Wilate or Nuwiq administered via intravenous injection
Study: NCT02041377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karajishi TS Investigational Blood Glucose Monitoring System
Description: Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study: NCT04421625

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test for SARS-Cov2 for patients and health staff
Description: Diagnostic test for SARS-CoV2 :~* Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~* Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~* Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)
Study: NCT04848922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot shower intervention
Description: Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
Study: NCT00369356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Bare metal stenting with administration of oral prednisone as described in the protocol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting coronary stent
Description: Stenting with DES (Cypher or Taxus)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bare metal coronary stent
Description: Stenting with BMS only
Study: NCT01662895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
Study: NCT00645983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile Extract
Description: 220 mg - 1100 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 5 capsules daily
Study: NCT02353533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: over- the- scope full- thickness resection device (FTRD)
Description: Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device

Intervention type: DEVICE
Group type: OTHER
Intervention: EMR
Description: Standard endoscopic mucosal resection using a resection snare
Study: NCT03521505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine arm
Description: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5\~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3\~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol arm
Description: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3\~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration.
Study: NCT01537211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C leg compared to subject's mechanical leg (Otto Bock)
Description: comparison of different prosthetic knees

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C leg compared to subject's mechanical leg (Otto Bock)
Description: comparison of different prosthetic knees
Study: NCT00961883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-B
Description: New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-B
Description: New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-B
Description: New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-B
Description: New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for injection, delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for injection, delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for injection, delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for injection, delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^9 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^8 PFU
Study: NCT01515657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 Aspirin Capsules
Description: 325 mg aspirin; once per day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-Release Aspirin Tablets
Description: 325 mg aspirin; once per day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated aspirin caplets
Description: 325 mg aspirin; once per day for 3 days
Study: NCT06106854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: SystemCHANGE
Description: six-month SystemCHANGE™ intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Six patient education booklets
Study: NCT03958552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
Study: NCT02849132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: oral entecavir 0.5mg daily for 8 years
Study: NCT02357498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphenoidal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphenoidal surgery